This analysis examines the historical and forecast performance for Servier in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Servier’s performance against key rivals in the ethical pharmaceutical sector
See how Servier’s outlook will be shaped primarily by the launch of generic copies of its largest product, Coversyl, in 2007
Evaluate Servier’s strategy of expanding globally, gaining a significant presence in emerging markets.
